WO2001002391A3 - Bicyclic aromatic compounds for treating drug addiction - Google Patents

Bicyclic aromatic compounds for treating drug addiction Download PDF

Info

Publication number
WO2001002391A3
WO2001002391A3 PCT/EP2000/005735 EP0005735W WO0102391A3 WO 2001002391 A3 WO2001002391 A3 WO 2001002391A3 EP 0005735 W EP0005735 W EP 0005735W WO 0102391 A3 WO0102391 A3 WO 0102391A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
alkylene chain
optionally
methylene
Prior art date
Application number
PCT/EP2000/005735
Other languages
French (fr)
Other versions
WO2001002391A2 (en
Inventor
Graham Paul Luscombe
Patricia Lesley Needham
Original Assignee
Knoll Ag
Graham Paul Luscombe
Patricia Lesley Needham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag, Graham Paul Luscombe, Patricia Lesley Needham filed Critical Knoll Ag
Priority to AU58174/00A priority Critical patent/AU5817400A/en
Priority to MXPA01013411A priority patent/MXPA01013411A/en
Priority to JP2001507828A priority patent/JP2003503491A/en
Priority to EP00943852A priority patent/EP1198234A2/en
Priority to CA002378389A priority patent/CA2378389A1/en
Publication of WO2001002391A2 publication Critical patent/WO2001002391A2/en
Publication of WO2001002391A3 publication Critical patent/WO2001002391A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof in which A is methylene or -O-; B is methylene or -O-; and g is 0, 1, 2, 3 or 4; R1 represents, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylthio, hydroxy, acyloxy, hydroxymethyl, cyano, alkanoyl, alkoxycarbonyl, optionally N-substituted carbamoyl, carbamoylmethyl, sulphamoyl or sulphamoylmethyl, an amino group optionally substituted by one or two alkyl groups, or two adjacent R1 groups together with the carbon atoms to which they are attached form a fused benz ring; R2 is H, alkyl or alkoxy; R3 and R4, which are the same or different, are H, or alkyl; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group of formula (IIa, IIb or IIc) in which V is a bond or an alkylene chain optionally substituted by one or more alkyl; V' is an alkylene chain optionally substituted by one or more alkyl; X is a bond or an alkylene chain and X' is an alkylene chain, provided that the total number of carbon atoms in X and X' amounts to 3 or 4; R5 is H, or alkyl; and T represents an optionally substituted aromatic group which optionally contains one or more N atoms, provided that T is not 2-pyrimidinyl when A is -O-; have utility in reducing cravings to food or an addictive substance.
PCT/EP2000/005735 1999-07-05 2000-06-21 Bicyclic aromatic compounds for treating drug addiction WO2001002391A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU58174/00A AU5817400A (en) 1999-07-05 2000-06-21 Therapeutic agents
MXPA01013411A MXPA01013411A (en) 1999-07-05 2000-06-21 Therapeutic agents.
JP2001507828A JP2003503491A (en) 1999-07-05 2000-06-21 Therapeutic agent
EP00943852A EP1198234A2 (en) 1999-07-05 2000-06-21 Bicyclic aromatic compounds for treating drug addiction
CA002378389A CA2378389A1 (en) 1999-07-05 2000-06-21 Therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9915616.8 1999-07-05
GBGB9915616.8A GB9915616D0 (en) 1999-07-05 1999-07-05 Therapeutic agents

Publications (2)

Publication Number Publication Date
WO2001002391A2 WO2001002391A2 (en) 2001-01-11
WO2001002391A3 true WO2001002391A3 (en) 2001-07-12

Family

ID=10856595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005735 WO2001002391A2 (en) 1999-07-05 2000-06-21 Bicyclic aromatic compounds for treating drug addiction

Country Status (7)

Country Link
EP (1) EP1198234A2 (en)
JP (1) JP2003503491A (en)
AU (1) AU5817400A (en)
CA (1) CA2378389A1 (en)
GB (1) GB9915616D0 (en)
MX (1) MXPA01013411A (en)
WO (1) WO2001002391A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1237158A (en) * 1969-07-31 1971-06-30 Inst Toxikologii Min Zdravookh Pharmaceutical compositions containing and process for preparing a benzodiopane derivative
WO1995007274A1 (en) * 1993-09-06 1995-03-16 Knoll Ag Bicyclic aromatic compounds as therapeutic agents
WO1997003071A1 (en) * 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Heterocyclylcarboxamide derivatives and their use as therapeutic agents
WO1997043279A1 (en) * 1996-05-10 1997-11-20 Janssen Pharmaceutica N.V. 2,4-diaminopyrimidine derivates as dopamine d4 receptor antagonists
WO1998040386A1 (en) * 1997-03-11 1998-09-17 Knoll Aktiengesellschaft Dioxino derivatives and their use as therapeutic agents
WO1999062902A1 (en) * 1998-06-03 1999-12-09 Knoll Aktiengesellschaft N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1237158A (en) * 1969-07-31 1971-06-30 Inst Toxikologii Min Zdravookh Pharmaceutical compositions containing and process for preparing a benzodiopane derivative
WO1995007274A1 (en) * 1993-09-06 1995-03-16 Knoll Ag Bicyclic aromatic compounds as therapeutic agents
WO1997003071A1 (en) * 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Heterocyclylcarboxamide derivatives and their use as therapeutic agents
WO1997043279A1 (en) * 1996-05-10 1997-11-20 Janssen Pharmaceutica N.V. 2,4-diaminopyrimidine derivates as dopamine d4 receptor antagonists
WO1998040386A1 (en) * 1997-03-11 1998-09-17 Knoll Aktiengesellschaft Dioxino derivatives and their use as therapeutic agents
WO1999062902A1 (en) * 1998-06-03 1999-12-09 Knoll Aktiengesellschaft N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors

Also Published As

Publication number Publication date
CA2378389A1 (en) 2001-01-11
WO2001002391A2 (en) 2001-01-11
MXPA01013411A (en) 2002-07-30
GB9915616D0 (en) 1999-09-01
JP2003503491A (en) 2003-01-28
EP1198234A2 (en) 2002-04-24
AU5817400A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
NZ507760A (en) Amide derivatives and nociceptin antagonists
WO2002030890A8 (en) Nitrogenous five-membered ring compounds
WO2005044793A3 (en) Nitrogen-containing fused heterocyclic compounds
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
AU8345491A (en) Heterocyclic derivatives
NZ512884A (en) Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
UA66825C2 (en) Azapolycyclic compounds condensed with aryl
TW200510441A (en) Novel compounds
TW349098B (en) Naphthalene derivatives, process for the preparation thereof, and intermediates therefor
HK1026700A1 (en) 1,4-Substituted cyclic amine derivatives or dihydroindole derivatives and medicament thereof.
MX9702244A (en) 1,2,3,4-tetrahydroquinoxalindione derivative.
CA2228044A1 (en) Dibenzimidazole radioprotectors
EP1167367A4 (en) Thienopyrimidine compounds and salts thereof and process for the preparation of the same
PL348392A1 (en) Novel diphenylurea compounds, method of obtaining them and pharmacological preparations containing such compounds
IE802612L (en) Bicyclo £2.2.1| heptane derivatives
EP0409406A3 (en) Aryl-substituted amine derivatives useful in cancer therapy
WO2001062705A3 (en) Aminoalcohol derivatives
WO2002048122A3 (en) Benzamidine derivatives
WO2004064721A3 (en) A pyrazolopyrimidine compound and a process for preparing the same
WO2001002391A3 (en) Bicyclic aromatic compounds for treating drug addiction
CA2262997A1 (en) Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
IL148548A0 (en) Bicyclic vasopressin agonists
IL103021A0 (en) Imidazoindolizine derivatives,their preparation and pharmaceutical compositions containing them
UA87480C2 (en) Spiropiperidine derivatives for controlling pests and intermediate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/013411

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2378389

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000943852

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000943852

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10019921

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000943852

Country of ref document: EP